Plasma Fractionation Market size was valued at USD 27.1 billion in 2022 and is expected to reach USD 43.52 billion By 2030 and grow at a CAGR of 6.1% over the forecast period of 2023-2030.
The term plasma fractionation Market describes the Market for goods and services related to plasma fractionation on a global scale. To produce certain therapeutic products, plasma fractionation separates different plasma components, such as proteins, enzymes, and antibodies. Following that, these goods are applied to a variety of medical conditions, such as autoimmune diseases, bleeding disorders, and immunodeficiency disorders. Blood donation, separating plasma from blood cells, fractionating plasma proteins, and purifying particular components are all processes in plasma fractionation. Albumin, immunoglobulins, coagulation factors, and alpha-1 antitrypsin are just a few products produced from the resultant plasma.
.png)
Over the past few years, blood plasma fractionation has become more popular on a global scale. Red blood cells make up around 44% of the blood, with plasma making up about 55%. As blood is collected and the plasma is separated to complete the process known as blood plasma fractionation, demand is anticipated to increase due to the increase in the number of blood banks. Blood plasma fractionation has also seen an increase in its therapeutic applications, which is anticipated to significantly contribute to the Market's growth. According to information provided by the Indian government, there are about 2,700 blood banks in the country, and they have been donating about 10 million units of blood annually. The Market for plasma fractionation is heavily regulated and subject to strict quality and safety requirements. Pharmaceutical corporations, biotechnology companies, and specialised plasma fractionation companies are major Market participants. These businesses make research and development investments in order to implement cutting-edge technologies and boost the effectiveness of plasma fractionation procedures. The Market for plasma fractionation is expanding as a result of variables such as rising knowledge of plasma-derived medicines, improvements in plasma fractionation methods, and rising albumin and immunoglobulin demand. Further highlighting the value of plasma-derived products, particularly convalescent plasma, in treating severe patients is the COVID-19 pandemic.
Production of the therapeutic proteins and antibodies employed in the treatment of various diseases depends critically on plasma fractionation.
Strategic partnerships and collaborations.
In order to improve their product portfolios, increase their Market presence, and make use of one another's knowledge, businesses in the plasma fractionation sector are forging strategic alliances and partnerships. These partnerships frequently result in the creation of cutting-edge goods and technology, stimulating Market expansion.
Restrain
Alternative medicines like biologics built using recombinant DNA technology compete with plasma-derived products.
Adverse incidents and worries about product safety.
Even though plasma fractionation methods have strict safety controls in place, unfavourable occurrences and safety issues with plasma-derived products can nevertheless happen. Such occurrences may result in regulatory reviews, product recalls, and a decline in consumer confidence, which may affect the Market's development and standing.
Opportunity
Beyond their conventional medicinal usage, plasma-derived products are finding new uses.
Growing Attention to Immunotherapy.
A growing number of diseases, including cancer, autoimmune disorders, and infectious diseases, are being treated using immunotherapy, including monoclonal antibodies and immunoglobulins. By creating and providing plasma-derived products for these uses, the plasma fractionation Market can take advantage of the expanding interest in immunotherapy.
Challenge:
The Market for plasma fractionation is heavily regulated, with strict standards for compliance, safety, and quality.
Product recalls and safety concerns.
Adverse events or safety issues with plasma-derived products might happen despite strict safety procedures. Product recalls or safety alerts may result in a decline in customer trust and increased regulatory scrutiny, which could affect the market's development and reputation. For market participants, ensuring product safety and upholding strict quality control standards are crucial difficulties.
Convalescent plasma was in greater demand during COVID-19 because doctors first used it to treat virus-infected patients. For instance, convalescent plasma was extensively used internationally to treat patients hospitalised with coronavirus and stop the progression of the disease, according to a Frontiers paper from June 2021. According to studies, convalescent plasma transfusion has been linked to better symptomatology and virus clearance. As a result, plasma fractions were originally needed in increasing amounts to treat the COVID-19 patient. The analysed Market is anticipated to have steady expansion throughout the course of the study's prediction period as the epidemic has faded and fewer people are becoming infected with the virus. The increasing use of immunoglobulins in various therapeutic fields, the expanding elderly population, the rising prevalence of uncommon diseases, and the rising number of plasma collection facilities globally are some of the specific factors driving Market expansion. For instance, the percentage of people in the world over 60 will nearly triple by 2050, according to WHO statistics from October 2022. The old population of the globe is expected to age far more quickly than in the past by 2050, with 80% of them living in low- and middle-income nations. As a result, the burden of uncommon diseases is predicted to rise globally along with the ageing population, raising the demand for plasma fractionation products and propelling the development of the Market under investigation.
We constantly track and update news in light of the ongoing political and economic unpredictability caused by the Russia-Ukraine conflict. Around the world, negative effects are anticipated, particularly in Eastern Europe, the European Union, Eastern and Central Asia, and the United States. This claim has negatively impacted people's lives and means of subsistence, and substantially disturbed trade patterns. It is anticipated that the ongoing conflict and unpredictability in Eastern Europe will negatively affect Ukraine and have severe, long-lasting impacts on Russia. In light of the most recent information on the war and the world's responses, the paper explores the implications for demand-supply balances, pressure on pricing variations, influence on import/export and trading, and short-term suggestions for the global plasma fractionation Market.
Impact of Ongoing Recession
Over the past two years, prices have increased significantly as a result of the high inflation rates in industrialised nations around the world. It is anticipated that aggregate purchasing power will considerably affect developing economies and is thought to be beneficial in many ways. The paper reveals how high inflation affects the long-term health of the global economy and offers information on the fiscal measures that can be taken to lessen its short-term effects on demand and supply, cash flow, and currency exchange. Given the associated effects of cost-push and demand-pull inflation, the Global Plasma Fractionation Market research projects a high rate of inflation.
By Product
Albumin
Von Willebrand Factor
PCC
By Application
Neurology
Immunology
Hematology
Rheumatology
By End User
Hospitals
Clinics
Clinical Research
.png)
North America
USA
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Rest of Europe
Asia-Pacific
Japan
South Korea
China
India
Australia
Rest of Asia-Pacific
The Middle East & Africa
Israel
UAE
South Africa
Rest of the Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
North America: The plasma fractionation Market in North America has historically been significant. The region has a strong regulatory environment, a well-established healthcare infrastructure, and a high frequency of chronic disorders. Due to its substantial patient population, favourable reimbursement practises, and considerable R&D investments, the United States dominates the industry. Canada is a significant player in the business as well. Plasma fractionation technology is improving in the area, and personalised medicine is getting more attention.
Asia Pacific: The plasma fractionation Market is expanding quickly in this region. In nations like China, Japan, and South Korea, healthcare spending is rising, the healthcare infrastructure is getting better, and people are becoming more aware of items made from plasma. The number of patients in the area is considerable, and chronic diseases are becoming more common. Rising healthcare investments and better access to healthcare are also making emerging economies like India and Southeast Asian nations appealing to Markets for plasma fractionation.
The major key players are Bio Products Laboratory (BPL), Biotest AG, China Biologic Products Holdings, Inc., CSL Limited, Japan Blood Products Organisation, Kedrion S.p.A., LFB Group, Octapharma AG, Sanquin, Shanghai RAAS. And the final reports list additional participants.
CSL Limited: To prevent acute attacks of hereditary angioedema (HAE), CSL Behring K. received manufacturing and Marketing approval from the Ministry of Health, Labour, and Welfare of Japan in 2022 for Berinert S.C. Injection 2000, a lyophilized human C1-esterase inhibitor concentrate for subcutaneous (SC) injection in plasma fractionation derivative.
Octapharma AG: In 2022, Octapharma AG stated that the European Union (EU) had expanded the indication for the subcutaneously administered human immunoglobulin cutaquig. Patients with acquired immune weaknesses would benefit from more flexible treatment options as a result of the extension.
| Report Attributes | Details |
| Market Size in 2022 | US$ 27.1 Bn |
| Market Size by 2030 | US$ 43.52 Bn |
| CAGR | CAGR of 6.1% From 2023 to 2030 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Historical Data | 2020-2021 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Albumin, Von Willebrand Factor, PCC) • By Application (Neurology, Immunology, Hematology, Rheumatology) • By End User (Hospitals, Clinics, Clinical Research) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Bio Products Laboratory (BPL), Biotest AG, China Biologic Products Holdings, Inc., CSL Limited, Japan Blood Products Organisation, Kedrion S.p.A., LFB Group, Octapharma AG, Sanquin, Shanghai RAAS |
| Key Drivers | • Production of the therapeutic proteins and antibodies employed in the treatment of various diseases depends critically on plasma fractionation. • Strategic partnerships and collaborations. |
| Market Opportunities | • Beyond their conventional medicinal usage, plasma-derived products are finding new uses. • Growing Attention to Immunotherapy. |
Ans: The Plasma Fractionation Market size was valued at USD 27.1 Billion in 2022
Ans: The Plasma Fractionation market is to grow at 6.1% Over the Forecast Period 2023-2030.
Ans: The Plasma Fractionation market is to Hit USD 43.52 Billion by 2030.
Ans: Plasma proteins are separated through a process called fractionation, which modifies their solubility.
Ans: Bio Products Laboratory (BPL), Biotest AG, China Biologic Products Holdings, Inc., CSL Limited, Japan Blood Products Organisation, Kedrion S.p.A., LFB Group, Octapharma AG, Sanquin, Shanghai RAAS
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 COVID 19 Impact Analysis
4.2 Impact of Russia and Ukraine War
4.3 Impact of ongoing recession
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Global Human Insulin Market Segmentation, By Product
8.1 Albumin
8.2 Von Willebrand Factor
8.3 PCC
9. Plasma Fractionation Market Segmentation, By Application
9.1 Neurology
9.2 Immunology
9.3 Hematology
9.4 Rheumatology
10. Plasma Fractionation Market Segmentation by End User
10.1 Hospital Pharmacy
10.2 Online pharmacy
10.3 Retails
11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 North America Plasma Fractionation Market by Country
11.2.2North America Plasma Fractionation Market by Product
11.2.3 North America Plasma Fractionation Market by Application
11.2.4 North America Plasma Fractionation Market by End User
11.2.5 USA
11.2.5.1 USA Plasma Fractionation Market by Product
11.2.5.2 USA Plasma Fractionation Market by Application
11.2.5.3 USA Plasma Fractionation Market by End User
11.2.6 Canada
11.2.6.1 Canada Plasma Fractionation Market by Product
11.2.6.2 Canada Plasma Fractionation Market by Application
11.2.6.3 Canada Plasma Fractionation Market by End User
11.2.7 Mexico
11.2.7.1 Mexico Plasma Fractionation Market by Product
11.2.7.2 Mexico Plasma Fractionation Market by Application
11.2.7.3 Mexico Plasma Fractionation Market by End User
11.3 Europe
11.3.1 Europe Plasma Fractionation Market by Country
11.3.3.2 Europe Plasma Fractionation Market by Product
11.3.3 Europe Plasma Fractionation Market by Application
11.3.4 Europe Plasma Fractionation Market by End User
11.3.5 Germany
11.3.5.1 Germany Plasma Fractionation Market by Product
11.3.5.2 Germany Plasma Fractionation Market by Application
11.3.5.3 Germany Plasma Fractionation Market by End User
11.3.6 UK
11.3.6.1 UK Plasma Fractionation Market by Product
11.3.6.2 UK Plasma Fractionation Market by Application
11.3.6.3 UK Plasma Fractionation Market by End User
11.3.7 France
11.3.7.1 France Plasma Fractionation Market by Product
11.3.7.2 France Plasma Fractionation Market by Application
11.3.7.3 France Plasma Fractionation Market by End User
11.3.8 Italy
11.3.8.1 Italy Plasma Fractionation Market by Product
11.3.8.2 Italy Plasma Fractionation Market by Application
11.3.8.3 Italy Plasma Fractionation Market by End User
11.3.9 Spain
11.3.9.1 Spain Plasma Fractionation Market by Product
11.3.9.2 Spain Plasma Fractionation Market by Application
11.3.9.3 Spain Plasma Fractionation Market by End User
11.3.10 The Netherlands
11.3.10.1 Netherlands Plasma Fractionation Market by Product
11.3.10.2 Netherlands Plasma Fractionation Market by Application
11.3.10.3 Netherlands Plasma Fractionation Market by End User
11.3.11 Rest of Europe
11.3.11.1 Rest of Europe Plasma Fractionation Market by Product
11.3.11.2 Rest of Europe Plasma Fractionation Market by Application
11.3.11.3 Rest of Europe Plasma Fractionation Market by End User
11.4 Asia-Pacific
11.4.1 Asia Pacific Plasma Fractionation Market by Country
11.4.2 Asia Pacific Plasma Fractionation Market by Product
11.4.3 Asia Pacific Plasma Fractionation Market by Application
11.4.4 Asia-Pacific Plasma Fractionation Market by End User
11.4.5 Japan
11.4.5.1 Japan Plasma Fractionation Market by Product
11.4.5.2 Japan Plasma Fractionation Market by Application
11.4.5.3 Japan Plasma Fractionation Market by End User
11.4.6 South Korea
11.4.6.1 South Korea Plasma Fractionation Market by Product
11.4.6.2 South Korea Plasma Fractionation Market by Application
11.4.6.3 South Korea Plasma Fractionation Market by End User
11.4.7 China
11.4.7.1 China Plasma Fractionation Market by Product
11.4.7.2 China Plasma Fractionation Market by Application
11.4.7.1 China Plasma Fractionation Market by End User
11.4.8 India
11.4.8.1 India Plasma Fractionation Market by Product
11.4.8.2 India Plasma Fractionation Market by Application
11.4.8.3 India Plasma Fractionation Market by End User
11.4.9 Australia
11.4.9.1 Australia Plasma Fractionation Market by Product
11.4.9.2 Australia Plasma Fractionation Market by Application
11.4.9.3 Australia Plasma Fractionation Market by End User
11.4.10 Rest of Asia-Pacific
11.4.10.1 APAC Plasma Fractionation Market by Product
11.4.10.2 APAC Plasma Fractionation Market by Application
11.4.10.3 APAC Plasma Fractionation Market by End User
11.5 The Middle East & Africa
11.5.1 The Middle East & Africa Plasma Fractionation Market by Country
11.5.2 The Middle East & Africa Plasma Fractionation Market by Product
11.5.3 The Middle East & Africa Plasma Fractionation Market by Application
11.5.4 The Middle East & Africa Plasma Fractionation Market by End User
11.5.5 Israel
11.5.5.1 Israel Plasma Fractionation Market by Product
11.5.5.2 Israel Plasma Fractionation Market by Application
11.5.5.3 Israel Plasma Fractionation Market by End User
11.5.6 UAE
11.5.6.1 UAE Plasma Fractionation Market by Product
11.5.6.2 UAE Plasma Fractionation Market by Application
11.5.6.3 UAE Plasma Fractionation Market by End User
11.5.7 South Africa
11.5.7.1 South Africa Plasma Fractionation Market by Product
11.5.7.2 South Africa Plasma Fractionation Market by Application
11.5.7.3 South Africa Plasma Fractionation Market by End User
11.5.8 Rest of Middle East & Africa
11.5.8.1 Rest of Middle East & Asia Plasma Fractionation Market by Product
11.5.8.2 Rest of Middle East & Asia Plasma Fractionation Market by Application
11.5.8.3 Rest of Middle East & Africa Plasma Fractionation Market by End User
11.6 Latin America
11.6.1 Latin America Plasma Fractionation Market by Country
11.6.2 Latin America Plasma Fractionation Market by Product
11.6.3 Latin America Plasma Fractionation Market by Application
11.6.4 Latin America Plasma Fractionation Market by End User
11.6.5 Brazil
11.6.5.1 Brazil Plasma Fractionation Market by Product
11.6.5.2 Brazil Africa Plasma Fractionation Market by Application
11.6.5.3 Brazil Plasma Fractionation Market by End User
11.6.6 Argentina
11.6.6.1 Argentina Plasma Fractionation Market by Product
11.6.6.2 Argentina Plasma Fractionation Market by Application
11.6.6.3 Argentina Plasma Fractionation Market by End User
11.6.7 Rest of Latin America
11.6.7.1 Rest of Latin America Plasma Fractionation Market by Product
11.6.7.2 Rest of Latin America Plasma Fractionation Market by Application
11.6.7.3 Rest of Latin America Plasma Fractionation Market by End User
12. Company profile
12.1 Bio Products Laboratory (BPL)
12.1.1 Market Overview
12.1.2 Financials
12.1.3 Product/Services/Offerings
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 Biotest AG
12.2.1 Market Overview
12.2.2 Financials
12.2.3 Product/Services/Offerings
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 China Biologic Products Holdings, Inc.
12.3.1 Market Overview
12.3.2 Financials
12.3.3 Product/Services/Offerings
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 CSL Limited
12.4.1 Market Overview
12.4.2 Financials
12.4.3 Product/Services/Offerings
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 Japan Blood Products Organisation
12.5.1 Market Overview
12.5.2 Financials
12.5.3 Product/Services/Offerings
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 Kedrion S.p.A
12.6.1 Market Overview
12.6.2 Financials
12.6.3 Product/Services/Offerings
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 LFB Group
12.7.1 Market Overview
12.7.2 Financials
12.7.3 Product/Services/Offerings
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 Octapharma AG
12.8.1 Market Overview
12.8.2 Financials
12.8.3 Product/Services/Offerings
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 Sanquin
12.9.1 Market Overview
12.9.2 Financials
12.9.3 Product/Services/Offerings
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10 Shanghai RAAS
12.10.1 Market Overview
12.10.2 Financials
12.10.3 Product/Services/Offerings
12.10.4 SWOT Analysis
12.10.5 The SNS View
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share Analysis
13.3 Recent Developments
14. Used Cases and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Digital Hearing Aids Market is expected to grow at a CAGR of 7.2% during the forecasted period 2024-2031.
The Preeclampsia Diagnostics Market size was valued at USD 1.07 Billion in 2022 and is expected to reach USD 1.24 Billion By 2030 and grow at a CAGR of 2.4% over the forecast period of 2023-2030.
The Long-term Care Software Market Size was valued at USD 2.77 billion in 2022, and expected to reach USD 7.33 billion by 2030, and grow at a CAGR of 12.9% over the forecast period 2023-2030.
The Clinical Decision Support Systems Market Size was valued at USD 5.08 billion in 2022 and is expected to reach USD 11.04 billion by 2030, and grow at a CAGR of 10.2% over the forecast period 2023-2030.
The Biopreservation Market size was estimated USD 2.2 billion in 2022 and is expected to reach USD 16.2 billion by 2030 at a CAGR of 28.4% during the forecast period of 2023-2030.
The Diabetes Drug Market size was estimated at USD 53.1 billion in 2022 and is projected to hit around USD 77.3 billion by 2030, growing at a CAGR of 4.9% during the forecast period 2023 to 2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
